The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025Company ...

Celebrating a Liverpool Legend’s Contributions to Football and CharityLiverpool’s Graeme Souness, an iconic figure in British ...

For years, he has been an active vice president of DEBRA UK, a charity devoted to supporting those affected by Epidermolysis ...

FDA allows for continued dosing of subjects in Phase 1 trial of ZKN-013 Following successful dosing of the initial subjects, FDA has allowed continued dosing of healthy volunteers for ZKN-013 for the ...

Graeme Souness has been made a CBE for his services to football and charity. The former Rangers and Liverpool star said ...

Graeme Souness has said fundraising for a charity has allowed people to see “the real me” as he was made a CBE at Windsor ...

Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.

About prademagene zamikeracel (pz-cel) Prademagene zamikeracel (pz-cel), Abeona’s investigational autologous, COL7A1 gene therapy, is currently being developed for the treatment of recessive ...

12-year-old Casey Connors is a sixth class student in Clondalkin, and suffers from the most severe form of Epidermolysis Bullosa, otherwise known as Butterfly Skin, which can cause extensive ...